High-Intensity Focused Ultrasound Enhanced Anti-Tumor Activities of Paclitaxel in Breast Cancer in vitro and in vivo.
breast cancer
cancer therapy
high-intensity focused ultrasound
paclitaxel
Journal
Cancer management and research
ISSN: 1179-1322
Titre abrégé: Cancer Manag Res
Pays: New Zealand
ID NLM: 101512700
Informations de publication
Date de publication:
2022
2022
Historique:
received:
14
11
2021
accepted:
31
01
2022
entrez:
7
4
2022
pubmed:
8
4
2022
medline:
8
4
2022
Statut:
epublish
Résumé
Paclitaxel (PTX) is an important oncologic chemotherapeutic agent against breast cancer, but breast cancer patients develop significant resistance to PTX during chemotherapy. Alterations in tubulin and associated proteins have been implicated in resistance to PTX. High-intensity focused ultrasound (HIFU) induces deep tumor penetration of anti-tumor agents in solid tumors. We investigated the influence of HIFU on the anti-tumor activities of PTX in breast cancer. Both in vivo and in vitro experiments were performed in this research: mice were treated with 2 mg/Kg PTX through tail vein injection, while breast cancer cells were treated with 400 nM PTX. Cell viability was analyzed through Cell Counting Kit-8. Cell apoptosis was evaluated through Annexin-V/PI Apoptosis Analysis Kit. The activities of catalase (CAT) and superoxide dismutase (SOD) and the concentration of malondialdehyde (MDA) were evaluated by relative commercial kits. HIFU enhanced PTX-inhibited breast cancer cell viability and PTX-induced cell apoptosis. Simultaneous treatment of HIFU and PTX decreased the activities of CAT and SOD and increased the concentration of MDA. In mice bearing MDA-MB-231 tumors, the treatment of HIFU and PTX significantly decreased tumor size, increased body weight and elevated animal survival. HIFU enhanced the distribution of PTX in tumor tissues. The performance of HIFU promoted the distribution of PTX and enhanced its anti-tumor activities in breast cancer.
Sections du résumé
Background
UNASSIGNED
Paclitaxel (PTX) is an important oncologic chemotherapeutic agent against breast cancer, but breast cancer patients develop significant resistance to PTX during chemotherapy. Alterations in tubulin and associated proteins have been implicated in resistance to PTX. High-intensity focused ultrasound (HIFU) induces deep tumor penetration of anti-tumor agents in solid tumors.
Methods
UNASSIGNED
We investigated the influence of HIFU on the anti-tumor activities of PTX in breast cancer. Both in vivo and in vitro experiments were performed in this research: mice were treated with 2 mg/Kg PTX through tail vein injection, while breast cancer cells were treated with 400 nM PTX. Cell viability was analyzed through Cell Counting Kit-8. Cell apoptosis was evaluated through Annexin-V/PI Apoptosis Analysis Kit. The activities of catalase (CAT) and superoxide dismutase (SOD) and the concentration of malondialdehyde (MDA) were evaluated by relative commercial kits.
Results
UNASSIGNED
HIFU enhanced PTX-inhibited breast cancer cell viability and PTX-induced cell apoptosis. Simultaneous treatment of HIFU and PTX decreased the activities of CAT and SOD and increased the concentration of MDA. In mice bearing MDA-MB-231 tumors, the treatment of HIFU and PTX significantly decreased tumor size, increased body weight and elevated animal survival. HIFU enhanced the distribution of PTX in tumor tissues.
Conclusion
UNASSIGNED
The performance of HIFU promoted the distribution of PTX and enhanced its anti-tumor activities in breast cancer.
Identifiants
pubmed: 35386184
doi: 10.2147/CMAR.S349409
pii: 349409
pmc: PMC8978695
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1303-1312Informations de copyright
© 2022 Chen et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest in this work.
Références
Proc Natl Acad Sci U S A. 1993 Oct 15;90(20):9552-6
pubmed: 8105478
J Cell Physiol. 2000 Apr;183(1):108-16
pubmed: 10699972
Lancet Oncol. 2014 Jun;15(7):e279-89
pubmed: 24872111
Int J Hyperthermia. 2015 May;31(3):302-9
pubmed: 25367011
Int J Hyperthermia. 2021 Sep;38(2):75-80
pubmed: 34420446
J Nat Prod. 1987 Nov-Dec;50(6):1095-9
pubmed: 3443858
Int J Cancer. 2006 Jul 1;119(1):41-8
pubmed: 16450384
ACS Nano. 2014 Oct 28;8(10):9874-83
pubmed: 25119793
Cancer Chemother Biol Response Modif. 1997;17:59-79
pubmed: 9551209
J Oncol Pharm Pract. 2021 Apr 16;:10781552211006182
pubmed: 33861657
Oncologist. 1998;3(6):373-389
pubmed: 10388129
J Control Release. 2017 Oct 10;263:68-78
pubmed: 28257990
Ann Surg Oncol. 2015 May;22(5):1441-6
pubmed: 25727556
Nature. 2013 Sep 19;501(7467):346-54
pubmed: 24048067
Phytother Res. 2021 Sep;35(9):5143-5153
pubmed: 34164855
Curr Opin Cell Biol. 1998 Feb;10(1):123-30
pubmed: 9484604
Mol Biol Cell. 2014 Sep 15;25(18):2677-81
pubmed: 25213191
Proc Natl Acad Sci U S A. 1981 Sep;78(9):5608-612
pubmed: 6117858
Pharmaceutics. 2020 Oct 15;12(10):
pubmed: 33076520
Integr Cancer Ther. 2021 Jan-Dec;20:1534735420988343
pubmed: 33543655
J Clin Oncol. 2005 Aug 20;23(24):5542-51
pubmed: 16110015
J Oncol Pharm Pract. 2021 Jan;27(1):108-118
pubmed: 32264745
FASEB J. 2001 Mar;15(3):719-30
pubmed: 11259390
Int J Hyperthermia. 2018 May;34(3):284-291
pubmed: 28715967
Adv Drug Deliv Rev. 2001 Mar 1;46(1-3):149-68
pubmed: 11259838
Neurol Res. 2017 Jan;39(1):73-82
pubmed: 27809706
Int J Neuropsychopharmacol. 2020 Apr 23;23(4):207-216
pubmed: 31967315
Colloids Surf B Biointerfaces. 2014 Jul 1;119:137-44
pubmed: 24881526
J Endourol. 2017 Apr;31(S1):S30-S37
pubmed: 28355119
J Pharm Pharm Sci. 2014;17(1):136-53
pubmed: 24735765
Cancers (Basel). 2019 Oct 09;11(10):
pubmed: 31600958
Cancer Biol Ther. 2011 Aug 15;12(4):260-9
pubmed: 21646863
Int J Mol Sci. 2020 Jan 08;21(2):
pubmed: 31936346
Cell Mol Biol Lett. 2019 Jun 13;24:40
pubmed: 31223315
Anticancer Res. 2020 Jan;40(1):281-286
pubmed: 31892577
Breast Cancer Res. 2010;12 Suppl 2:S2
pubmed: 21050423
Curr Med Chem. 2021;28(25):5179-5188
pubmed: 33176628
J Control Release. 2012 Aug 20;162(1):218-24
pubmed: 22732476
Nano Converg. 2017;4(1):30
pubmed: 29170724
Biochim Biophys Acta. 2008 Apr;1785(2):96-132
pubmed: 18068131
BMJ Open. 2020 Nov 26;10(11):e040162
pubmed: 33243800
Biochim Biophys Acta. 2000 Aug 15;1459(2-3):397-404
pubmed: 11004456
Iran J Pathol. 2020 Spring;15(2):117-126
pubmed: 32215027
Oncotarget. 2011 May;2(5):368-77
pubmed: 21576762
Cancer Res. 2000 May 1;60(9):2497-503
pubmed: 10811131
Annu Rev Pharmacol Toxicol. 1999;39:361-98
pubmed: 10331089
Cancer Chemother Pharmacol. 2011 Sep;68(3):553-7
pubmed: 21713447
Proc Natl Acad Sci U S A. 2011 Feb 8;108(6):2426-31
pubmed: 21245339
Front Bioeng Biotechnol. 2019 Nov 22;7:324
pubmed: 31824930
Biomolecules. 2019 Nov 27;9(12):
pubmed: 31783552